Despite an improvement in clinical status, unlike patients with pulmonary arterial hypertension, the mortality in systemic sclerosis has not improved since the introduction of epoprostenol. CHEST Journal, June 6 2013. (Also see: Pulmonary Hypertension Prognosis and Flolan/Prostacyclin/Epoprostenol)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.